Cargando…
Prevalence of the HLA-B*5701 Allele and Abacavir Hypersensitivity in Saudi HIV Patients: A Multicenter Study
Introduction Human immunodeficiency virus (HIV) incidence and prevalence are increasing in Saudi Arabia, with a total prevalence of 12,000 in 2020. Treatment of HIV patients includes multiple regimens that may involve abacavir (ABC), which is a potent drug for treating HIV and can be used as a singl...
Autores principales: | Alsaeed, Ali, Alkhadrawi, Zahra, Alsadah, Batool, Almudhry, Zakia, AlBayat, Hawra, Alhadad, Fadel, Dahlawi, Albaraa, Abu Ali, Batool, Al muhainy, Badr, Alhaddad, Taher A, Alhaddad, Mousa J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10693910/ https://www.ncbi.nlm.nih.gov/pubmed/38050529 http://dx.doi.org/10.7759/cureus.48229 |
Ejemplares similares
-
HLA-B*5701 testing to predict abacavir hypersensitivity
por: Ma, Joseph D., et al.
Publicado: (2010) -
Prevalence of HLA-B*5701 and Its Relationship with Abacavir Hypersensitivity Reaction in Iranian HIV-Infected Patients
por: Baniasadi, Shadi, et al.
Publicado: (2016) -
Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B*5701 Screening as a Risk‐Mitigation Measure
por: Stainsby, Chris M., et al.
Publicado: (2018) -
Frequency of HLA B*5701 allele carriers in abacavir treated-HIV infected patients and controls from northeastern Brazil
por: Crovella, Sergio, et al.
Publicado: (2011) -
Cost impact of prospective HLA-B*5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany
por: Wolf, E, et al.
Publicado: (2010)